Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection.
Saved in:
| Title: | Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection. |
|---|---|
| Authors: | Yuen RR; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Steiner D; Department of Medicine, Boston University School of Medicine, Boston, MA, United States., Pihl RMF; PiBS Program, Boston University School of Medicine, Boston, MA, United States., Chavez E; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Olson A; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States., Smith EL; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Baird LA; Department of Medicine, Boston University School of Medicine, Boston, MA, United States., Korkmaz F; Department of Medicine, Boston University School of Medicine, Boston, MA, United States., Urick P; Department of Medicine, Boston University School of Medicine, Boston, MA, United States., Sagar M; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.; Department of Medicine, Boston University School of Medicine, Boston, MA, United States.; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States., Berrigan JL; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Gummuluru S; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Corley RB; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States.; National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA, United States., Quillen K; Department of Medicine, Boston University School of Medicine, Boston, MA, United States., Belkina AC; Flow Cytometry Core Facility, Boston University School of Medicine, Boston, MA, United States.; Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, United States., Mostoslavsky G; Center for Regenerative Medicine, Boston University School of Medicine, Boston, MA, United States., Rifkin IR; Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, United States.; Renal Section, Department of Medicine, VA Boston Healthcare System, Boston, MA, United States., Kataria Y; Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, United States., Cappione AJ 3rd; MilliporeSigma, Burlington, MA, United States., Gao W; Antagen Pharmaceuticals, Boston, MA, United States., Lin NH; Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA, United States., Bhadelia N; Department of Medicine, Boston University School of Medicine, Boston, MA, United States.; National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA, United States., Snyder-Cappione JE; Department of Microbiology, Boston University School of Medicine, Boston, MA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2021 Apr 09; Vol. 12, pp. 614676. Date of Electronic Publication: 2021 Apr 09 (Print Publication: 2021). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
